Joint patent for using the BRCA1 gene as a therapy for cardiovascular disease

February 10, 2012

St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.

Dr. Subodh Verma, a at St. Michael's, and Dr. Mohammed Al-Omran, a vascular surgeon at the largest university in Saudi Arabia, are named as inventors on patent US 8, 110,185 B2 issued Feb. 7.

Obtaining the patent is an initial step in realizing the potential of this innovative approach to treating one of the leading causes of death in Canada,

Dr. Verma's team published three papers in 2011, in Nature Communications, the and Gene Therapy, showing how the BRCA1 and 2 genes, which normally suppresses the growth of breast and ovarian tumours, also protect the heart.

Following a heart attack, mice with the mutated had a three-to-five times higher rate of death. This was largely due to the development of profound heart failure and poor DNA damage repair, leading to larger and more severe heart attacks.

Dr. Verma said the mutated BRCA1 gene may prevent in that is essential to recovery after a heart attack.

"The patent is also significant because it demonstrates how collaborative research between St. Michael's and King Saud University can help speed the transfer of medical discoveries from the laboratory bench to patient bedsides," said Dr. Arthur Slutsky, vice-president of research.

St. Michael's and King Saud jointly own the invention. The hospital has an agreement with the university and the inventors on how to share royalties. The hospital also has a commercialization partner, PARTEQ innovations, the technology transfer arm of Queen's University.

Related Stories

Recommended for you

Blocking a gene reduces fat

July 29, 2015

By blocking the expression of a certain gene in patients, University of Montreal researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their blood, even in various severe ...

Study identifies 'major player' in skin cancer genes

July 27, 2015

A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases. Their findings shed light on an important ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.